Alkem Laboratories Limited (NSE:ALKEM)
5,535.00
+103.00 (1.90%)
Oct 29, 2025, 3:29 PM IST
Alkem Laboratories Revenue
Alkem Laboratories had revenue of 33.71B INR in the quarter ending June 30, 2025, with 11.19% growth. This brings the company's revenue in the last twelve months to 133.04B, up 4.49% year-over-year. In the fiscal year ending March 31, 2025, Alkem Laboratories had annual revenue of 129.65B with 2.34% growth.
Revenue (ttm)
133.04B
Revenue Growth
+4.49%
P/S Ratio
4.88
Revenue / Employee
7.08M
Employees
18,785
Market Cap
649.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 129.65B | 2.97B | 2.34% |
| Mar 31, 2024 | 126.68B | 10.68B | 9.21% |
| Mar 31, 2023 | 115.99B | 9.65B | 9.08% |
| Mar 31, 2022 | 106.34B | 17.69B | 19.96% |
| Mar 31, 2021 | 88.65B | 5.21B | 6.24% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Biocon | 157.71B |
| Glenmark Pharmaceuticals | 134.56B |
| Mankind Pharma | 129.10B |
Alkem Laboratories News
- 4 weeks ago - Alkem Laboratories transfers trade generics business to subsidiary Alkem Wellness, effective October 1 - Business Upturn
- 5 weeks ago - Alkem Laboratories launches pertuza biosimilar for treatment of HER2-positive breast cancer - Business Upturn
- 2 months ago - Stocks to watch on August 22: Key brokerage calls on cement, GMR Airports, Wipro, autos, Alkem Labs, Reliance, and HAL - Business Upturn
- 2 months ago - Nomura raises target price on Alkem Labs, says valuation attractive on domestic growth and Enzene prospects - Business Upturn
- 2 months ago - Alkem Labs shares jump 4% as Nomura maintains ‘Buy’ rating with Rs 5,430 target after strong Q1 results - Business Upturn
- 2 months ago - Stocks to watch on brokerages’ radar today, August 13: Minda Corp, Apollo Hospitals, Alkem Labs, Nykaa, Zydus Lifesciences, HAL, ONGC, NHPC, Honasa, Paytm - Business Upturn
- 2 months ago - Alkem Laboratories shares jump 6% on strong Q1 results - Business Upturn
- 2 months ago - Alkem Laboratories Q1 Results: Revenue jumps 11.2% YoY to Rs 3,371 crore, net profit up Rs 21.45% YoY - Business Upturn